Patent Losses Put a Costly Damper on Merck's Cubist Buy

Just hours after Merck's $8.4 billion acquisition of Cubist Pharmaceuticals was announced, a federal court invalidated most of the patents protecting the Cubist's top-selling antibiotic, Cubicin.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news